Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 46

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 46
---
 section titled “ —Outstanding Equity Awards at Fiscal Year-End ”.

#### Mirum Pharmaceuticals2025 Proxy Statement37

#### TABLE OF CONTENTS

#### Executive Compensation

#### Employment Offer Letters
Below are descriptions of our offer letters with our named executive officers. Each of our named executive officers’ base salary, target performance bonus and equity-based incentive awards for 2024 are discussed in the sections titled “— Base Salary ,” “— Bonus Compensation ” and “— Equity-Based Incentive Awards. ” For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see “ Executive Compensation—Potential Payments Upon Termination or Change in Contro l”.

Mr. Peetz. We entered into an offer letter with Mr. Peetz in December 2018 and an amended and restated offer letter in May 2019, which govern the terms of his employment with us. Pursuant to the agreement, Mr. Peetz is entitled to an annual base salary, an annual target performance bonus based on the attainment of specified objectives as determined by us and equity-based incentive awards granted in the discretion of the Compensation Committee, each as may be adjusted by the Compensation Committee from time to time. Mr. Peetz’s employment is at will.

Mr. Bjerkholt. We entered into an offer letter with Mr. Bjerkholt in August 2023, which governs the terms of his employment with us. Pursuant to the agreement, Mr. Bjerkholt is entitled to an annual base salary, an annual target performance bonus based on the attainment of specified objectives as determined by us and equity-based incentive awards granted in the discretion of the Compensation Committee, each as may be adjusted by the Compensation Committee from time to time. Mr. Bjerkholt’s employment is at will.

Mr. Radovich. We entered into an offer letter with Mr. Radovich in April 2020, which governs the terms of his employment with us. Pursuant to the agreement, Mr. Radovich is entitled to an annual base salary, an annual target performance bonus based on the attainment of specified objectives as determined by us and equity-based incentive awards granted in the discretion of the Compensation Committee, each as may be adjusted by the Compensation Committee from time to time. Mr. Radovich’s employment is at will.

Dr. Quan. We entered into an offer letter with Dr. Quan in January 202